At Novo Nordisk, patient safety is a top priority. As the sole manufacturer of FDA-approved medicines containing semaglutides, Novo Nordisk is deeply concerned by companies promoting and selling non-FDA-approved knock-off drugs that claim to contain the same “semaglutide.” As a result of the concerning dynamics in the marketplace, Novo Nordisk is committed to raising awareness of the dangers of compounded or knock-off “semaglutide”. Here are three important facts to know if you or someone you care for is considering an unapproved, compounded product.
Latest Posts
Partner News
Segal Benz: Boosting Engagement in Employee Well-Being Programs
Employee well-being—mental, physical, and financial—is a top priority for many organizations. When employees feel supported, ...
Read More
Partner News
Aon: 2025 Employee Sentiment Study
This study is based on findings from Aon’s Employee Sentiment survey and insights from Aon’s ...
Read More
Partner News
Wellthy: Where Care Meets Work – New Data on Caregiving and Backup Care Benefits
Caregiving has long been a reality for employees, and its impact on the workforce is ...
Read More